On the heels of a PhI­II im­plo­sion, can­cer biotech Molo­gen is turned over to the liq­uida­tor

The 31 staffers left at Ger­man biotech Molo­gen are now work­ing for a liq­uida­tor. And the fo­cus now is on find­ing buy­ers for any­thing it has left that can be sold.

Molo­gen filed for in­sol­ven­cy a few days ago, months af­ter its lead drug — the TLR9 ag­o­nist lefi­tolimod — failed bad­ly in Phase III.

Back in Au­gust the com­pa­ny re­port­ed that their drug pro­duced a near mir­ror im­age re­sult for me­di­an over­all sur­vival in com­par­i­son to the con­trol group in a Phase III. Their OS rate was 22 months when the drug was used as a sec­ond-line ther­a­py for col­orec­tal can­cer. That com­pared to 21.9 months for the com­par­i­son group. And sec­ondary end­points didn’t pro­vide any rea­son to hope for some­thing bet­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER